Merck & Co., Inc. (mrk)
MRK Financials
| Trailing P/E | 102.70 |
| Forward P/E | 13.37 |
| Price/Sales | 4.76 |
| Price/Book | 6.91 |
| Market cap | $317.05B |
| Avg volume | 10208537.0 |
| Shares outstanding | 2469824415.0 |
Merck & Co., Inc. FAQ
What does Merck & Co., Inc. (MRK) do?
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerb…
What is MRK's P/E ratio?
Merck & Co., Inc. has a trailing P/E of 102.70× based on publicly available market data.
Does MRK pay a dividend?
Indicated dividend yield: 2.6%. Confirm ex-dates and payout history in Vest Terminal.
What sector is MRK in?
Merck & Co., Inc. is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is MRK's market capitalization?
Approximate market cap: $317.05B.
What are the main risks for MRK?
Key risks include elevated valuation, among factors on this page.
What are the strengths of MRK?
Potential positives include revenue growth of 5.1% year-over-year, gross margin of 76.0% supports competitive unit economics.
Where can I get analyst estimates for MRK?
Consensus estimates, price targets, and detailed analyst data for Merck & Co., Inc. are available to Professional subscribers in Vest Terminal — not on this public summary page.